Rigel Pharmaceuticals has seen its consensus analyst price target rise from $38.33 to $45.40, indicating heightened optimism about the company’s financial trajectory. This optimism coincides with a ...

Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...

Rigel announced that R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did not meet the primary endpoint in a ...

Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M ...

Shares of Rigel Pharmaceuticals RIGL have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s ...

Rigel will participate in one-on-one meetings and present a company overview on Wednesday, September 3, at 8:35 a.m. ET. 2025 Wells Fargo Healthcare Conference in Boston, MA Rigel will participate in ...

Eli Lilly is paying Rigel Pharmaceuticals $125 million up front to grab a share in the development of drugs that would give the company a new way to address inflammation in multiple diseases. The ...

Ryan Maynard and Dolly Vance Promoted to Executive Vice Presidents SOUTH SAN FRANCISCO, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the ...